One hallmark of our industry is the incredible risks faced in bringing a new product to market.  New technologies bring risks of not performing the way we’d like.  Clinical and regulatory risks can delay or prevent approval.  Commercial and market risks may limit success with physicians, patients and customers.  All of this leads to huge financial risks for investors along the way, and we have seen this scenario play out repeatedly here in the local area in disappointing results for companies like Therion, Vion, and Acusphere. 
(more…)